ODD announces further validation of novel oncology therapeutic mechanism

Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour activity with efficacy comparable to that of rapamycin.

Credit: Oxford Drug Design

Using its GenAI platform, the company has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types

Register for FREE to keep reading

Join 12,000+ scientists, engineers, and IT professionals driving innovation through informatics, HPC, and simulation with:

Insights into HPC, AI, lab informatics & data
Curated content for life sciences, engineering & academia
Access to Breakthroughs: real-world computing success
Free reports & panels, including the Lab Informatics Guide
White Papers & software updates for smarter research

Sign up now

Already a member? Log in here

Your data is protected under our privacy policy.

Where hype meets reality: why breakthrough computing technologies must prove their scientific worth

High-performance computing, artificial intelligence, and quantum computing are transforming scientific research, enabling breakthroughs in drug discovery, climate modeling, and materials science. But how do we ensure billion-dollar investments in advanced computing infrastructure deliver tangible scientific value?